Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CDA | P32320 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15011109 | 1.00 | LMNA (0.53) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL20668807 | 1.00 | LMNA (0.53) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL20668805 | 1.00 | LMNA (0.53) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL15011373 | 0.90 | LMNA (0.53) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL14441078 | 0.90 | LMNA (0.53) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL10187890 | 0.90 | LMNA (0.53) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL25565426 | 0.90 | LMNA (0.42) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL15010651 | 0.89 | LMNA (0.55) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL15010648 | 0.89 | LMNA (0.55) | LMNAMTORALDH1A1TP53THRB | |
| Hydrogen Sulfide SCHEMBL28296750 | 0.88 | LMNA (0.54) | LMNAMTORALDH1A1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384740-B2 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2025-08-12 | — | — | US | claimed |
| CN-114450265-B | Cationic lipids and uses thereof | 菲克特生物科学股份有限公司 | 2024-12-24 | — | — | CN | claimed |
| US-20230373903-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | FACTOR BIOSCIENCE INC. | 2023-11-23 | — | — | US | claimed |
| US-11814333-B2 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20230193207-A1 | MESENCHYMAL STEM CELL THERAPIES | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | claimed |
| US-20230193231-A1 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | claimed |
| EP-4149252-A2 | ENGINEERED GENE-EDITING PROTEINS | Factor Bioscience Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| EP-4142744-A1 | MESENCHYMAL STEM CELL THERAPIES | Factor Bioscience Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| CN-115701285-A | Mesenchymal stem cell therapy | 菲克特生物科学股份有限公司 | 2023-02-07 | — | — | CN | claimed |
| US-20220106256-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | FACTOR BIOSCIENCE INC. | 2022-04-07 | — | — | US | claimed |
| US-11242311-B2 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2022-02-08 | — | — | US | claimed |
| WO-2021231549-A2 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. (US) | 2021-11-18 | — | — | WO | claimed |
| WO-2021222389-A1 | MESENCHYMAL STEM CELL THERAPIES | FACTOR BIOSCIENCE INC. (US) | 2021-11-04 | — | — | WO | claimed |
| US-20210032192-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | NOVELLUS, INC. | 2021-02-04 | — | — | US | claimed |
| US-10752576-B1 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2020-08-25 | — | — | US | claimed |
| US-10611722-B1 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2020-04-07 | — | — | US | claimed |
| US-20260144753-A1 | MULTIVALENT IONIZABLE LIPID DELIVERY SYSTEMS | FACTOR BIOSCIENCE INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260146264-A1 | METHODS FOR REPROGRAMMING AND GENE EDITING CELLS | FACTOR BIOSCIENCE INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032192-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-20220106256-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-10752576-B1 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-20230373903-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-12384740-B2 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-20260144753-A1 | MULTIVALENT IONIZABLE LIPID DELIVERY SYSTEMS | PLTP, SLC7A1, PCTP | LMNA 403/4885MTOR 2930/4885ALDH1A1 3704/4885 |
| US-10611722-B1 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-20260146264-A1 | METHODS FOR REPROGRAMMING AND GENE EDITING CELLS | ZMYND8, STING1, DCLRE1A | LMNA 2027/4885MTOR 3404/4885ALDH1A1 1643/4885 |
| US-11814333-B2 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-11242311-B2 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | LMNA 264/4885MTOR 4508/4885ALDH1A1 4835/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | LMNA 1076/4885MTOR 3184/4885ALDH1A1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.